Trump administration reclassifies cannabis as less dangerous

• Cannabis reclassified to lower scheduling category in the US, potentially facilitating increased clinical research and evidence generation on therapeutic applications
• Reclassification may improve access to medical cannabis products, allowing more patients to benefit from potential therapeutic effects where indicated
• UK doctors should monitor emerging evidence from US research programmes to inform understanding of cannabis's clinical efficacy, safety profile, and appropriate prescribing indications

Medical marijuana was moved into a lower category of drugs in order to increase research and access.

ClinicaliQ summarises and contextualises external updates for clinical awareness, then links to the original publisher for the full article and most current context.